PulseCath
- Company typePrivate
- Founded2007
- HeadquartersAmsterdam, Netherlands
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
PulseCath firmographics
Firmographics- Name
- PulseCath
- Legal name
- PulseCath BV
- Website
- https://pulsecath.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
PulseCath industry classification
Industry- Product category
- Mechanical Circulatory Support Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)
Keywords
Where PulseCath is headquartered
LocationHeadquarters
- HQ city
- Amsterdam
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
PulseCath business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Marketing or Sales, Personnel, Operations, Infrastructure
Revenue model
- Medical Device Sales: PulseCath generates revenue through the direct sale of its iVAC 2L circulatory support devices and related accessories (membrane pumps, PTFE inner tubes, demo kits, demonstration tools). The company sells to hospitals through a global network of 35+ distributor partners across 42+ countries.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels7 records
PulseCath product offering
Product offeringCore offering
PulseCath develops, manufactures, and markets the iVAC 2L, a percutaneous Ventricular Assist Device (pVAD) that provides short-term mechanical circulatory support for patients with impaired left ventricular function. The 17Fr transfemoral catheter with a patented rotating 2-way valve delivers up to 2L/min of pulsatile blood flow during high-risk PCI, cardiogenic shock, and complex cardiac interventions, and is driven by standard intra-aortic balloon pump (IABP) consoles already present in cath labs.
Product overview
PulseCath offers a focused product portfolio centered on the iVAC 2L family of percutaneous circulatory support devices. The core offering is the iVAC 2L, a pulsatile pVAD (percutaneous Ventricular Assist Device) that provides short-term mechanical circulatory support for patients with impaired left ventricular function. The product line includes the standard iVAC 2L (17Fr) and the newer iVAC 2L Sheathless Ready (SLR) variant with reduced vascular access requirements. Supporting the device portfolio are demonstration tools, training equipment, and the PulseCath Academy training platform. All iVAC 2L devices integrate with standard IABP consoles already present in cath labs worldwide, eliminating the need for dedicated hardware.
Differentiator
Problem solved
Functional benefit
Brands
- iVAC 2L: The iVAC 2L is a percutaneous circulatory support device (pVAD) that assists the pump function of the heart in patients with impaired left ventricular function.
- iVAC 2L SLR (Sheathless Ready)
Products and services
- iVAC 2L A percutaneous circulatory support device (pVAD) that assists the pump function of the heart in patients with impaired left ventricular function. It is a short-term, fully percutaneous, 17Fr transfemoral LVAD that generates up to 2L/min blood flow for hemodynamic support during high-risk PCI, cardiogenic shock, AMI, and complex ablation procedures.
- iVAC 2L Sheathless Ready (SLR) A variant of the iVAC 2L with a Sheathless Ready (SLR) design where the conical-shaped PTFE inner tube functions as a dilator, making the introducer sheath optional and providing the smallest vascular access of any mechanical circulatory support device on the market.
- iVAC 2L Demo Kit
Quantifiable outcome
- Six-month mortality: 8.3% with iVAC 2L vs 16.1% with IABP in high-risk PCI patients (Dr. Dragula comparative study, July 2025)
- +3 more outcomes
Companies that use PulseCath
Customer profileNamed customers14 records
Segments4 records
Ideal customer profiles3 records
PulseCath technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration10 records
Feature5 records
PulseCath partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core, standard and key opinion leader.
- Huadong Medicine Co., Ltd.coreStrategic collaboration to develop and commercialize the iVAC mechanical circulatory product in Greater China (China, Hong Kong, Macau). Partnership accelerates development and expands Huadong Medicine's medical portfolio for high-risk PCI cases with innovative percutaneous ventricle assist device. Local distribution in Hong Kong through Prism Technologies Limited and in Malaysia through Transmedic Pte Ltd.
- EUKON Srl (Italy)coreExclusive distributor for Italy. Co-hosted TEACH course at Ospedale Civile Ss. Antonio e Biagio e Cesare Arrigo, Alessandria with live case demonstrations.
- Intervene Medical Pty Ltd (Australia & NZ)standardExclusive distributor for Australia and New Zealand. Facilitated first iVAC 2L case in New Zealand at Waikato Hospital.
- ARF Medical SA de CV (Mexico)standardExclusive distributor for Mexico. Facilitated product registration and upcoming official launch.
- Global Leading Excellence LLC (Oman)standardDistributor for Oman. Facilitated first protected high-risk PCI at Royal Hospital Muscat.
- Avidal Group (Germany)coreDistribution partner in Germany that helped achieve NUB status 1 reimbursement in 300 German hospitals.
- Medaccess (Poland)standardExclusive distributor for Poland. Co-hosted Warsaw Course on Cardiovascular Interventions with live case demonstrations.
- Prof. Dr. med. Jan D. Schmittokey opinion leaderMedical advisor. Head of the Mechanical Circulatory Support Program at Hannover Medical Center, Germany. Key opinion leader contributing to clinical publications and research on pulsatile MCS.
- Prof. Dr. Nicolas M. van Mieghemkey opinion leaderMedical advisor. Medical Director of Interventional Cardiology at Thoraxcenter, Erasmus MC, Rotterdam, Netherlands. Led PULSE trial and multiple clinical studies; key opinion leader for high-risk PCI and MCS.
- 42+ Additional DistributorsstandardNetwork includes distributors in: Argentina (Endomedical S.R.L), Austria (Pacemed GmbH), Baltic Republics (American Baltic Technology), Belarus (Slimedis UAB), Belgium (TOP Medical), Brazil (Biomedical), Bulgaria (Medical Devices Ltd.), Costa Rica (Sumedical), Croatia (Sonimed d.o.o.), Czech Republic (Vamex), Eastern Europe (Niva GmbH), Egypt (Skypro/Skysmartmed), Nordic region (CardiRad Oy), France (Biosensors Europe SA), Greece & Cyprus (Medical Dynamics SA), Hungary (Cardiosolutions), India (Advanced Life Sciences), Israel (M.Fast), Jordan (D.M.Est.), Malta (EverCare Medical), Pakistan (TEK Enterprises), Panama (Twins & Martin), Peru (Cardiomed S.A.C.), Portugal (Endovascular Dispositivos Médicos), Romania (Medical Devices & Diagnostics), Serbia (Sanomed d.o.o.), Slovakia (GlobalMed), South Korea (Vasocare Co.), Spain, Sri Lanka (GEBS MED), Tunisia (MDiD), Turkey (Gama medikal), UK/Ireland (Dot Medical), Uruguay (Sanyfico SA), Venezuela (CDI MED LLC).
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
PulseCath competitors and assessment
Company assessmentBroad incumbents
- Boston Scientific: Diversified cardiovascular device manufacturer with structural heart and interventional cardiology portfolios that intersect with high-risk PCI procedures where iVAC 2L is used. Less direct in pVAD but addresses overlapping cath lab decision-makers.
- Teleflex: Major cardiovascular player with the Arrow IABP platform (one of the consoles PulseCath's iVAC 2L integrates with) and a portfolio that includes intra-aortic balloon catheters, making it a partial competitor and an integration partner to PulseCath.
- Abbott: Broad incumbent in cardiovascular devices, including the CentriMag acute circulatory support system and HeartMate 3 LVAD. Competes in adjacent temporary and durable MCS segments that overlap with PulseCath's positioning.
Emerging players
- Procyrion: Houston-based developer of the Aortix percutaneous mechanical circulatory support device for cardiogenic shock and high-risk PCI. A direct emerging competitor in the catheter-based pVAD category.
- Magenta Medical: Israel-based emerging developer of next-generation percutaneous ventricular assist devices (Elevate system) for high-risk PCI and cardiogenic shock. Represents a direct emerging competitive threat with newer technology targeting the same clinical indications as iVAC 2L.
- FineHeart: France-based developer of the Impulse dynamics/FLOWMAKER cardiac assist device for long-term mechanical circulatory support. An emerging player addressing heart failure with novel technology, partially overlapping with PulseCath's heart failure use cases.
- Supira Medical: Emerging developer of a next-generation percutaneous ventricular assist system targeting high-risk PCI and cardiogenic shock. Competes directly with PulseCath in the pVAD category with a focus on improving on Impella's design.
Direct peers
- Abiomed (Johnson & Johnson): The dominant player in percutaneous mechanical circulatory support with the Impella platform — the primary direct competitor to PulseCath's iVAC 2L in high-risk PCI and cardiogenic shock. Impella is the category leader and the most clinically entrenched pVAD globally.
- LivaNova (TandemHeart): Markets the TandemHeart pVAD system, a percutaneous transseptal LVAD used for temporary mechanical circulatory support. Direct competitor in the percutaneous LVAD category alongside PulseCath and Impella.
Others
- Cardiobridge (CytoSorbents / Xenios AG): Adjacent technology provider in mechanical circulatory support and blood-purification devices used in cardiac surgery and intensive care. Thematically related as an ecosystem participant in the broader MCS market, though not a direct pVAD competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
PulseCath social profiles
Digital presencePulseCath compliance and trust
Trust signalCompliance3 records
PulseCath financial estimates
Financial estimateRevenue estimate
Valuation estimate
PulseCath leadership team
Management profileNumber of profiles
Profiles6 records
PulseCath funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PulseCath M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PulseCath
What does PulseCath do?
PulseCath develops, manufactures, and markets the iVAC 2L, a percutaneous Ventricular Assist Device (pVAD) that provides short-term mechanical circulatory support for patients with impaired left ventricular function. The 17Fr transfemoral catheter with a patented rotating 2-way valve delivers up to 2L/min of pulsatile blood flow during high-risk PCI, cardiogenic shock, and complex cardiac interventions, and is driven by standard intra-aortic balloon pump (IABP) consoles already present in cath labs.
Is PulseCath a public or private company?
PulseCath is a private company. It is classified as venture growth investor backed and is currently operating.
When was PulseCath founded?
PulseCath was founded in 2007. It employs 1 to 10 people.
Where is PulseCath based?
PulseCath is headquartered in Amsterdam, Netherlands, in the Europe region.
How does PulseCath make money?
One revenue line is on record: medical Device Sales.
Who are PulseCath's main competitors?
Broad incumbents on record are Boston Scientific, Teleflex and Abbott. Emerging players are Procyrion, Magenta Medical, FineHeart and Supira Medical. Direct peers are Abiomed (Johnson & Johnson) and LivaNova (TandemHeart). Cardiobridge (CytoSorbents / Xenios AG) is listed as an others.
Does PulseCath have an API?
No public API is recorded for PulseCath.
What industry is PulseCath in?
PulseCath's product category is Mechanical Circulatory Support Devices. Its primary akta.pro industry code is HLAHAFAG, Mechanical Circulatory Support (VAD, IABP, ECMO). Its NAICS code is 334510 and its SIC code is 3841.